Introduction {#Sec1}
============

Mutations in genes such as *age-1* (Arking [@CR2]), *daf-2* (Kenyon et al. [@CR17]; Kimura et al. [@CR18]), *Indy* (Rogina et al. [@CR27]), and *chico* (Clancy et al. [@CR6]) have been found to increase life span in the laboratory organisms *Caenorhabditis elegans* and *Drosophila melanogaster*. Genetic manipulations offer helpful clues in identifying pathways for pharmacological interventions, but there is the possibility that these genetic manipulations result in adverse metabolic effects. In particular, there is the possibility that "longevity mutants" increase lifespan only because of a "refrigeration" effect. The "refrigeration" effect refers by analogy to the phenomenon in which an increase in lifespan is seen at environmentally low temperatures due to decreases in metabolic rate (Van Voorhies et al. [@CR35]). The inverse correlation between metabolic rate and longevity in *Drosophila* has been reported in a number of studies. It has been suggested that poikilotherms can have their lifespan extended or curtailed as their metabolic rates are decreased or increased, respectively (Finch [@CR11]; Rose [@CR28]). In a recent study, Van Voorhies et al. ([@CR36]) evaluated CO~2~ production in a large set of recombinant inbred *Drosophila* males at various ages. Although they reported a wide range of longevities and metabolic rates, no correlations between the two variables were observed. This contrasts with earlier experimental results, suggesting significant complexity in the relationship between lifespan and metabolic rate. As humans are homeotherms with a fairly stable metabolic rate, drugs that act via substantial lowering of metabolic rate, thus producing hypo metabolic syndromes, may not be appropriate candidates for anti-aging interventions. Poikilothermic animal models, such as *C. elegans* and *Drosophila*, have the ability to tolerate metabolic rate depression well during phases of poor environmental conditions or deprivation of nutrients (Klass et al. [@CR20]; Van Voorhies and Ward [@CR33]). Since humans do not posses the same capacity to endure such depression of their metabolism, it is necessary to evaluate metabolic rate as a confounding factor; especially when considering results that might be extrapolated to the clinical context.

Other potential confounds, such as fecundity depression, can also result in lifespan extension. These factors should also be evaluated during an anti-aging substance screening process (Jafari and Rose [@CR12]). Some compounds may increase lifespan simply by substantially depressing fecundity; a substantial depression in fecundity alone is sufficient to increase longevity in *Drosophila* (Smith [@CR32]). In order to ensure that the inferred anti-aging properties are a direct effect of the compound, and not adverse physiological changes, we need to assess the impact of the compound on other aspects of the organism's physiology. A number of studies in the anti-aging literature have addressed such secondary effects by evaluating the impact of the proposed anti-aging compound on fecundity and metabolic rate (Kang et al. [@CR16]; Jafari et al. [@CR13], [@CR14], [@CR15]). For instance, *Rhodiola rosea* increased *Drosophila* lifespan at certain doses but the fecundity was also reduced at those doses (Jafari et al. [@CR13]). Therefore, a fecundity assay is an important check for artifactual lifespan enhancement.

In addition to checking for the impact of compounds on physiological confounds of aging, we should also evaluate their effect on biomarkers of health span such as locomotor activity. In 1987, Le Bourg reported an association between locomotor activity and longevity in *Drosophila*. He showed that spontaneous locomotor activity declined in females as they aged and increased in males up to week five and then began to decrease (Le Bourg [@CR22]). In another recent study, locomotion declined with aging in *Drosophila* although males performed better than females at advanced age (Simon et al. [@CR31]).

Our study evaluated the impact of lamotrigine on lifespan, physiological confounds of aging, and health span of *D. melanogaster*. Although the mechanism of action of lamotrigine has yet to be fully understood, it is believed that the drug primarily targets voltage-sensitive sodium channels that inhibit neural excitation through the repression of the neurotransmitters glutamate and aspartate (Lang et al. [@CR21]). These neurotransmitters play key roles in numerous physiological activities of various species (Rock [@CR26]; Fagg and Foster [@CR10]; Wroblewski and Danysz [@CR39]; Advokat and Pellegrin [@CR1]; Navarro et al. [@CR24]; Burton and Kazemi [@CR3]). *Drosophila* possesses glutamate neurotransmitters that are regulated by sodium channels in their nervous system. Studies conducted on the anesthetic drug isoflurane have shown that *Drosophila* larvae exhibited decreased glutamate neurotransmitter release when treated with the drug. This decrease in neuronal firing is paralleled with a sedative phase where decreased locomotor activity was observed (Sandstrom [@CR30]), suggesting a conserved neuronal physiology shared by vertebrates and arthropods.

Due to lamotrigine inhibitory actions on the glutamate neurotransmitter and *Drosophila's* conserved neural physiology with respect to the glutamate receptor, relative to mammals, we hypothesized that a depression of metabolic rate and locomotor activity would be observed in flies supplemented with the drug.

Materials and methods {#Sec2}
=====================

*Drosophila* population employed {#Sec3}
--------------------------------

All *D. melanogaster* stocks used in these experiments were ultimately derived from a sample (called "IV") of the Amherst, Massachusetts, Ives population that was collected in 1975 and cultured at moderate to large population sizes ever since (Rose et al. [@CR29]). This population has been reared at controlled densities (50--80 eggs per vial) for more than 700 generations with discrete generations cultured every 2 weeks.

Drug administration {#Sec4}
-------------------

Fruit flies were supplemented with lamotrigine (GlaxoSmithKline) at 1, 3, 6, 12, 24, and 48 mg/ml, alongside controls that were handled in the same manner but not exposed to lamotrigine. These doses reflect the final concentration of lamotrigine in the yeast paste that was supplemented to adult flies during the experiment. Stock solutions were prepared by dissolving lamotrigine powder in water.

Mortality assay {#Sec5}
---------------

All flies used in these assays were raised as larvae in 5 ml of standard banana-molasses food at densities between 50 and 80 eggs per 8-dram vial. Populations were maintained at about 25°C with constant illumination. During the assays, adults were kept in standard 8-dram vials containing 5 ml of banana-molasses food and coated with 75 μl of the drug-yeast paste mixture. Adults were transferred to fresh vials and survivors were counted every 2 days over a 28 day period. For each dose, 320 males and 320 females were exposed to the compound. There were 4 males and 4 females in each vial, with a total of 80 vials per dose per sex, and the flies were transferred every other day during the aging phase (4 weeks for IV stocks). Data were analyzed by examining the number of surviving flies at the end of week four. The statistical evaluation at the end of week four is based on data accumulated from the records of survivors obtained every 2 days. Significant differences between the control and each drug treatment were assessed using the Pearson chi-square test. Mortality assays were replicated for doses that decreased the mortality rate. These doses were subsequently used in the lifespan assay.

Lifespan assay {#Sec6}
--------------

One hundred sixty male and 160 female flies were exposed to 0, 6, or 12 mg/ml of lamotrigine. There were 4 males and 4 females in each vial, with a total of 40 vials for each treatment. Survivorship was determined with every other day transfers until every fly was dead. A one-way ANOVA and Dunn's multiple comparison tests versus control were used to determine if there were significant differences in mean lifespan between the flies given lamotrigine and the control flies. Additionally, to test for significant differences in maximum lifespan a one-way ANOVA and Dunn's multiple comparison tests versus control were performed using the mean lifespan of the longest-lived ten percent.

Metabolic rate assay {#Sec7}
--------------------

Control and treated flies were reared for a 10-day period in a similar fashion to that of the mortality assay, as noted above. On day 11, flies were transferred into sex-specific vials containing their respective dosages of lamotrigine. There were 6 vials per dosage, each containing 4 flies. Metabolic rate was evaluated using the Licor LI-6260 gas analyzer. CO~2~ production in treated flies was compared to that of the control group handled and assayed in parallel. A flow-through respirometer was used to measure the rate of CO~2~ release from groups of flies following the methods of Williams et al. ([@CR37]). Room air was passed through a small chamber containing soda lime, two silica gel chambers, and a Drierite/Ascarite/Drierite column. This produced a stream of CO~2~^−^ free air that was forwarded into the chambers of the flies being measured at a rate of 100 ml/min. The air was directed by a series of computer-controlled valves (Sable Systems, Las Vegas, NV, USA) that allowed separate chambers to be measured in turn. The vials were assayed in a random sequence, allowing for a sampling which was unbiased to temporal and environmental conditions. CO~2~ levels were averaged and recorded every second using the data acquisition software DATACAN V (Sable Systems). Each vial was measured for 20 min. During periods when they were not being measured, the flies were kept in a flow of dry, CO~2~-free air by flushing with a separate air stream. The last 5 min of each 20 min recording of CO~2~ release was averaged to provide an estimate of relative metabolic rate. The effects of drug treatments on metabolic rates were analyzed with a one-way ANOVA using drug level treated as a fixed effect.

Locomotion assay {#Sec8}
----------------

Locomotion studies were conducted to assess the effects of lamotrigine on *Drosophila* locomotor activity at week one and four of age. Male and female flies were exposed to 0, 6, or 12 mg/ml of lamotrigine and tested for locomotor activity using the automated *Drosophila* activity monitor DAM2 (Trikinetics, MA). After 1 and 4 weeks of lamotrigine exposure flies were lightly anesthetized for the purpose of sex classification and to be transferred into the 5 mm tubes needed for the DAM2 system. To avoid CO~2~-dependent reductions in locomotor activity as well as to control for any new stimulus that may affect activity, flies were given a 30-min acclimation period prior to be placed in the channels of the monitor. Following the acclimation period data were collected for individual flies at 30-s intervals for a 45-min period resulting in a total of 90 readings per fly.

Any animal with a reading that exceeded the population mean by two SD at any given 30-s interval was excluded from that interval statistical analysis, as abnormally high numbers in activity may have resulted from activity that was localized to the detector beam region. Any animals that had a total number of movements less than two SD from the population mean were excluded, since scores of zero could be due to deaths that occurred in the process of transferring the flies into the 5 mm tubes.

Repeated measures ANOVA was used to determine significant differences in activity between the three treatment groups. Bonferroni's multiple comparison tests versus control was used to measure significant differences in activity between the control flies and the lamotrigine fed flies.

Fecundity assay {#Sec9}
---------------

We evaluated age-specific fecundities using the same dosing protocols as above, except that the flies were handled with one female and one male in each assay vial. Fecundity was assayed from day 1 to 10 of adult life. The number of eggs laid each day by each individual female was recorded for this period of 10 days. The impact of drugs on fecundity was assessed by a one-way ANOVA. We also compared the 10-day fecundity of control females to the pooled data from all three doses using a standard *t*-test on the mean values.

Results {#Sec10}
=======

In our dose finding assays, we evaluated the impact of a wide dosing range (1, 3, 6, 12, 24 and 48 mg/ml) of lamotrigine on fly mortality (data not shown). For both males and females, lamotrigine treatment at 6 or 12 mg/ml resulted in statistically significant decreases in mortality (*P* \< 0.05 for both; conducted in duplicate and triplicate, respectively) and 24 mg/ml of lamotrigine resulted in a statistically significant decrease in mortality for females only (*P* \< 0.05; conducted in duplicate) (Fig. [1](#Fig1){ref-type="fig"}). Lamotrigine was found to be toxic in both males and females at 48 mg/ml. Since 6 and 12 mg/ml of lamotrigine resulted in the highest mortality reduction in both male and female flies, these doses were chosen to conduct the lifespan assay.Fig. 1The effect of lamotrigine on mortality rate at 0, 6, 12 and 24 mg/ml. The bars display SEM. \* *P* \< 0.01, \*\* *P* \< 0.001

Lamotrigine increased mean lifespan in males and females at both 6 and 12 mg/ml, and it increased maximum lifespan in males and females at 12 mg/ml (Fig. [2](#Fig2){ref-type="fig"}). At 6 mg/ml, mean lifespan was increased by 2.6 days (12.0%) in males (*P* \< 0.05) and 3.1 days (12.8%) in females (*P* \< 0.05). At 12 mg/ml, mean and maximum lifespan in males were increased by 3.3 days (15.4%) and 6.5 days, respectively; and in females by 4.2 days (17.2%) and 6.3 days, respectively (*P* \< 0.01, *P* \< 0.001 for mean increases).Fig. 2The effect of lamotrigine on the lifespan of female (**a**) and male (**b**) flies. In both sexes, lamotrigine resulted in a significant increase in mean lifespan at six (*P* \< 0.05) and 12 mg/ml (*P* \< 0.01) and increased maximum lifespan at 12 mg/ml (*P* \< 0.001). Values on the table are means ± SEM and units are days

To determine if the observed reduction in mortality was a direct effect of lamotrigine treatment or due to a secondary physiological effect caused by drug-induced physiological changes, we examined metabolic rates following lamotrigine treatment. We found a trend towards metabolic rate depression in both males and females (Fig. [3](#Fig3){ref-type="fig"}). When comparing controls with combined lamotrigine treatment arms, we found that treated males showed a statistically significant depression in metabolic rate (*P* \< 0.05) and treated females displayed a trend towards a metabolic rate depression (*P* = 0.23).Fig. 3The impact of 0, 6, 12 and 24 mg/ml of lamotrigine on metabolic rate of adult male and female flies. No statistically significant differences were observed. The bars display SEM

Lamotrigine supplemented flies showed a decrease in locomotor activity at week one and four of feeding. At week one, 6 mg/ml treatment resulted in a 7% reduction in locomotion in males and a 15% reduction in females (*P* \< 0.05 for both). At week one, 12 mg/ml treatment caused a 55% decrease in locomotor activity in females only (*P* \< 0.001). At week four, 6 and 12 mg/ml decreased locomotion in males by 32 and 29%, respectively (*P* \< 0.001, *P* \< 0.0001). At week four, both 6 and 12 mg/ml caused a 27% reduction in locomotion in females (*P* \< 0.01 for both) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4The effect of lamotrigine on the locomotor activity of 1 week old male flies (**a**), 4 weeks old male flies (**b**), 1 week old female flies (**c**), and 4 weeks old female flies (**d**). \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001

It was found that lamotrigine did not impact fecundity, as no significant differences existed between control flies compared to treated flies (*P* \< 0.703).

Discussion {#Sec11}
==========

In our study, the anticonvulsive lamotrigine increased mean and maximum lifespan in male and female *Drosophila*, but compromised the fly health span, as revealed by a significant decrease in locomotion and a trend towards a depression in metabolic rate. Further, lamotrigine was not found to affect fly fecundity.

Although there are limited studies on anticonvulsants and aging, one report provided evidence that ethosuximide or trimethadione, two commonly prescribed anticonvulsants, increased mean and maximum life-span of *C. elegans* (Evason et al. [@CR9]). These two drugs have been found to reduce low-threshold calcium currents in thalamic neurons, which is consistent with their anticonvulsant actions in absence seizures (Coulter et al. [@CR7]). Since most anticonvulsants act as mood stabilizers they may shift *C. elegans* toward a dauer-like state---a semi-dormant, quiescent state where *C. elegans* decrease their metabolic rate in response to environmental stresses. Therefore, the increased lifespan observed with ethosuximide- and trimethadione-treatment may be due to a decreased metabolic rate.

Lamotrigine anticonvulsive activity is thought to occur through the inhibition of sodium channels, hindering the release of glutamate and aspartate from the axon terminal of neurons (Lang et al. [@CR21]). These neurotransmitters have been implicated in a wide range of physiological functions, such as learning and memory, metabolic processes, and the regulation of respiration, among others (Rock [@CR26]; Fagg and Foster [@CR10]; Wroblewski and Danysz [@CR39]; Advokat and Pellegrin [@CR1]; Navarro et al. [@CR24]; Burton and Kazemi [@CR3]). The trend in metabolic rate depression that we observed in this study could be due to lamotrigine inhibitory effect on glutamate and aspartate and their roles in respiratory regulation. Although this specific mechanistic hypothesis was not tested in our study, we propose that the neurotransmitters' effect on respiration and their ultimate effect on the metabolic rate could have resulted in lamotrigine-induced life span extension.

It has long been established that reduced metabolic rates can increase poikilotherm life spans. This has been demonstrated in *C. elegans* and house flies exposed to low temperatures, as well as house flies restricted in activity through the prevention of flight (Ragland and Sohal [@CR25]; Klass [@CR19]; Yan and Sohal [@CR40]). Complementary studies have also shown that increasing the metabolism of honeybees and kestrels results in a decrease in life span (Wolf and Schmid-Hempel [@CR38]; Daan et al. [@CR8]). In spite of these earlier observations, a recent work reported no correlation between longevity and metabolic rate in recombinant inbred *Drosophila* (Van Voorhies et al. [@CR34]).

Since caloric restriction has been consistently found to increase longevity in mammals and invertebrates, there is the bare possibility that the presence of lamotrigine in the food may induce lower levels of food consumption. This could, in effect, mimic an effect similar to dietary restriction. It is well established that grossly depressed fecundity is associated with dietary restriction sufficient to significantly increase *Drosophila* longevity (Chippendale et al. [@CR5]). In order to test for possible caloric restriction effects in lamotrigine-supplemented *Drosophila*, we measured the number of eggs produced over a 10 day period, finding no significant differences in reproductive output when treating with lamotrigine. Since egg production is proportional to food level, the absence of a decline in fecundity indicates that the *Drosophila* females were not lowering their levels of lamotrigine-supplemented food consumption (Chapman and Partridge [@CR4]). Additionally, the dietary restriction enhancement of longevity observed by Chippendale et al. ([@CR5])using the same type of stock of fruit flies as those used here, required a several-fold reduction in fecundity, we concluded that the extension of life-span which we have observed is not due to a dietary restriction effect mediated by reduced fecundity. Thus, it appears that the effect of lamotrigine on the longevity of adult flies was not mediated solely through effects on some aspect(s) of reproduction.

Since aging is defined by a number of physiological and behavioral changes across the lifespan of an organism, anti-aging compounds should increase lifespan without compromising health span. The association between locomotor activity and aging has been established in a variety of species. A lamotrigine-induced decrease in locomotion is consistent with previous studies. At week one, 6 mg/ml of lamotrigine resulted in a 7% reduction in locomotion in males and 15% in females (*P* \< 0.05) and 12 mg/ml caused a 55% decrease in locomotor activity in females only (*P* \< 0.001). These observations are consistent with the finding that the performance of female flies declines more rapidly with aging (Le Bourg [@CR23]). At week four, 6 and 12 mg/ml decreased locomotion in males and females to a comparable extent (27--32%). The significant reduction in locomotion at weeks one and four suggest that anti-aging effects of lamotrigine are associated with compromised function, and in this sense a reduced health span.

In conclusion, the observed decrease in mortality and increase in lifespan as a result of lamotrigine was associated with depression in locomotion and metabolic rate, without a reduction in fecundity. Our results suggest that assessing appropriate indicators of health span is critical in the course of identifying and discovering anti-aging compounds.
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